Drugging the undruggable RAS: Mission Possible?
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For more than 40 years, KRAS mutation has been considered “undruggable” [16, 17].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For many proteins known to be involved in driving diseases, such as KRAS in many cancers, conventional drug development strategies often aimed at developing inhibitors have failed [118, 119].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [119]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Research works printed but not linked: 1
- Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655 (2012). · DOI · Paper page
Cited by
Items 301–400 of 1,007
Targeting Krasg12c‐mutant cancer with a mutation‐specific inhibitor
Christensen, J. G., Olson, P., Briere, T., Wiel, C., & Bergo, M. O. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13057 · Cited by 76
“The challenges have included 1) lack of pockets large enough for small molecules to bind; 2) high affinity for GTP which prevents direct targeting of the nucleotide-binding pocket; 3) high intracellular GTP concentrations and fast nucleotide exchange cycles that hinders competition; and 4) potential toxicity arising f…”
BackgroundZhou, Y., Zou, Y., Yang, M., Mei, S., Liu, X., Han, H., Zhang, C.-D., & Niu, M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c12075 · Cited by 79
The RAS–Effector Interaction as a Drug Target
Keeton, A. B., Salter, E. A., & Piazza, G. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0938 · Cited by 77
“However, there have been notable successes, such as combinations of MEK inhibitors with other targeted therapeutics in the case of malignant melanoma (4).”
BackgroundInfluentialBhayadia, R., Krowiorz, K., Haetscher, N., Jammal, R., Emmrich, S., Obulkasim, A., Fiedler, J., Schwarzer, A., ROUHI, A. M., Heuser, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2204 · Cited by 85
Kim, J. W., Márquez, C. P., Kostyrko, K., Koehne, A. L., Marini, K. D., Simpson, D. R., Lee, A. G., Leung, S. G., Sayles, L. C., Shrager, J. B., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0612-2 · Cited by 84
Targeting loss of heterozygosity for cancer-specific immunotherapy
Hwang, M. S., Mog, B. J., Douglass, J., Pearlman, A. H., Hsiue, E. H.-C., Paul, S., DiNapoli, S. R., Konig, M. F., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022410118 · Cited by 83
A bulky glycocalyx fosters metastasis formation by promoting G1 cell cycle progression
Woods, E. C., Barnes, J. M., Pickup, M. W., Pedram, K., Kai, F., Hollander, M. J., Weaver, V. M., & Bertozzi, C. R. (2017) · eLife · doi:10.7554/elife.25752 · Cited by 80
Bahrami, A., Hassanian, S. M., Shahidsales, S., Farjami, Z., Hasanzadeh, M., Anvari, K., Aledavood, A., Maftouh, M., Ferns, G. A., Khazaei, M., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25890 · Cited by 78
Therapeutics Targeting Mutant KRAS
Thein, K. Z., Biter, A. B., & Hong, D. S. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-033145 · Cited by 72
Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
Marcus, K., & Mattos, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2148 · Cited by 75
“Contrary to what is observed in all other oncogenic mutants, the water-mediated network from the g-phosphate to the nucleotide sensing residues in helix 5 is intact in both structures ofRASG12D, and thismay contribute to the effectiveness and frequency of this mutant in human cancers (20, 28).”
BackgroundPrecision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles
Strand, M. S., Krasnick, B. A., Pan, H., Zhang, X., Bi, Y., Brooks, C., Wetzel, C., Sankpal, N., Fleming, T., Goedegebuure, S. P., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27109 · Cited by 74
“Indeed, in the 35 years since its discovery [18], KRAS has been the target of many attempts at pharmaceutical inhibition, including direct inhibition, interference with post-translational modification, disruption of membrane association, and interaction with downstream effectors [19].”
BackgroundThe Function of RAS Mutation in Cancer and Advances in its Drug Research
Chen, S., Li, F., Xu, D., Hou, K., Fang, W., & Li, Y. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190506122228 · Cited by 83
The Role and Function of Ras-association domain family in Cancer: A Review
Zinatizadeh, M. R., Momeni, S. A., Zarandi, P. K., Chalbatani, G. M., Dana, H., Mirzaei, H. R., Akbari, M. E., & Miri, S. R. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.07.008 · Cited by 79
“Also, the inhibition of RASSF1A in cells induces the apoptosis induced by DNA damage, and is treated with cisplatin.(10,11) These observations indicate that, epigenetic therapy is designed to restore the expression of the RASSF protein, and may be a valid strategy to treat aggressive Raspositive and RASSF-negative sup…”
BackgroundKRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Xie, M., Xu, X., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672612 · Cited by 74
“Inhibition of the Nucleotide Exchange Cycles The conversion of inactive KRAS-GDP to active KRAS-GTP requires GEFs, including the most common one, the Son of Sevenless (SOS) protein (39).”
BackgroundMolecules linked to Ras signaling as therapeutic targets in cardiac pathologies
Ramos-Kuri, M., Meka, S. H., Salamanca‐Buentello, F., Hajjar, R. J., Lipskaia, L., & Chemaly, E. R. (2021) · Biological Research · doi:10.1186/s40659-021-00342-6 · Cited by 74
“This hypervariable region bears very little identity between the Ras isoforms, as little as 15%, and contains the important CAAX box (C = cysteine, A = apolar amino acid and X = serine or methionine) in the carboxyl end of the protein, where the farnesyl lipid is attached [18, 19].”
BackgroundDrugging K-RasG12C through covalent inhibitors: Mission possible?
Ni, D., Li, X., He, X., Zhang, H., Zhang, J., & Lu, S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.007 · Cited by 73
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma
Leung, G. P., Feng, T., Sigoillot, F. D., Geyer, F. C., Shirley, M. D., Ruddy, D. A., Rakiec, D. P., Freeman, A. K., Engelman, J. A., Jaskelioff, M., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0327 · Cited by 73
“In RAS/RAF-mutant tumors, much of the negative regulation of the upstream nodes of the pathway is ineffective (39, 40).”
BackgroundNew tricks for human farnesyltransferase inhibitor: cancer and beyond
Wang, J., Yao, X., & Huang, J. (2017) · MedChemComm · doi:10.1039/c7md00030h · Cited by 73
Inhibitors of Ras–SOS Interactions
Lu, S., Jang, H., Zhang, J., & Nussinov, R. (2016) · ChemMedChem · doi:10.1002/cmdc.201500481 · Cited by 72
Palma, G., Khurshid, F., Lu, K., Woodward, B., & Husain, H. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00237-5 · Cited by 72
Peng, D. H., Rodriguez, B. L., Diao, L., Gaudreau, P.-O., Padhye, A., Konen, J. M., Ochieng, J. K., Class, C. A., Fradette, J. J., Gibson, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22875-w · Cited by 72
Zhong, X., Zheng, L., Shen, J., Zhang, D., Xiong, M., Zhang, Y., He, X., Tanyi, J. L., Yang, F., Montone, K. T., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00079-16 · Cited by 73
Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 82
Chen, S.-H., Gong, X., Zhang, Y., Horn, R. D. V., Yin, T., Huber, L., Burke, T., Manro, J. R., Iversen, P. W., Wu, W., et al. (2017) · Oncogene · doi:10.1038/onc.2017.384 · Cited by 77
RAF kinase dimerization: implications for drug discovery and clinical outcomes
Brummer, T., & McInnes, C. (2020) · Oncogene · doi:10.1038/s41388-020-1263-y · Cited by 74
Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain
Antic, I., Biancucci, M., Zhu, Y., Gius, D. R., & Satchell, K. J. F. (2015) · Nature Communications · doi:10.1038/ncomms8396 · Cited by 75
Molecular Pathology of Lung Cancer
Saller, J. J., & Boyle, T. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037812 · Cited by 98
GTP Hydrolysis Without an Active Site Base: A Unifying Mechanism for Ras and Related GTPases
Calixto, A. R., Moreira, C., Pabis, A., Kötting, C., Gerwert, K. B., Rudack, T., & Kamerlin, S. C. L. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b03193 · Cited by 72
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 70
“PDAC are enriched in KRAS, KRAS, and KRAS point mutations (10).”
BackgroundPrakash, P., Hancock, J. F., & Gorfe, A. A. (2015) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24786 · Cited by 69
Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It’s Down
Hobbs, G. A., Wittinghofer, A., & Der, C. J. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.015 · Cited by 68
“RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated gene family in human cancers (Cox et al., 2014).”
BackgroundSelf-citationHonokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
Luo, L.-X., Li, Y., Liu, Z.-Q., Fan, X.-X., Duan, F.-G., Li, R.-Z., Yao, X.-J., Leung, E. L.-H., & Liu, L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00199 · Cited by 68
“Compared to KRAS-GTP interaction, the relatively poor binding affinity of these compounds prompted a widely held perception that oncogenic KRAS was an “undruggable” cancer target (Cox et al., 2014).”
BackgroundAssessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3438 · Cited by 67
“Most KRAS mutations in lung cancer reside in codon 12, with major populations including G12C (44%), G12D (17%), and G12V (23%) of all KRAS mutations (9).”
BackgroundSimpson, L. M., Macartney, T. J., Nardin, A., Fulcher, L. J., Röth, S., Testa, A., Maniaci, C., Ciulli, A., Ganley, I. G., & Sapkota, G. P. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.06.013 · Cited by 66
“However, the therapeutic targeting of K-RAS, either by conventional pharmacological inhibition (Cox et al., 2014; Papke and Der, 2017) or targeted degradation (Zeng et al.”
BackgroundDiscovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer
Cheng, J., Li, Y., Wang, X., Dong, G., & Sheng, C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00929 · Cited by 63
ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
Jaiswal, B. S., Durinck, S., Stawiski, E. W., Yin, J., Wang, W., Lin, E., Moffat, J. G., Martin, S. E., Modrusan, Z. D., & Seshagiri, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3674 · Cited by 76
Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer
Henry, J. T., Coker, O., Chowdhury, S., Shen, J. P., Morris, V. K., Dasari, A., Raghav, K., Nusrat, M., Kee, B., Parseghian, C., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00256 · Cited by 66
Ponz‐Sarvisé, M., Corbo, V., Tiriac, H., Engle, D. D., Frese, K. K., Oni, T. E., Hwang, C., Öhlund, D., Chio, I. I. C., Baker, L. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1398 · Cited by 69
“Therefore, alternative approaches have often focused on developing agents that target two downstream effector pathways, the MAPK and the PI3K signaling cascades (10).”
BackgroundSantarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-639 · Cited by 65
“The intrinsic biochemical characteristics of RAS led to consider it as an “undruggable” target in lung cancer (9,19).”
BackgroundInfluentialProgress in targeting RAS with small molecule drugs
McCormick, F. (2019) · Biochemical Journal · doi:10.1042/bcj20170441 · Cited by 64
Wang, Y., Ji, D., Lei, C., Chen, Y., Qiu, Y., Li, X., Li, M., Ni, D., Pu, J., Zhang, J., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.044 · Cited by 67
“Small molecules that target proteins’ interfaces between Ras and its regulators/effectors, such as Sulindac and DCAI, have been shown to inhibit Ras–Raf and Ras–SOS interactions [19], respectively.”
BackgroundRicciuti, B., Leonardi, G. C., Metro, G., Grignani, F., Paglialunga, L., Bellezza, G., Baglivo, S., Mencaroni, C., Baldi, A., Zicari, D., et al. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1115349 · Cited by 65
“To this regard, novel alternative targeted strategies of enhancing apoptosis (MEK + BCL2/BCL-XL inhibition) or targeting PI3K upstream (MEK + IGF1R inhibition) have already entered the clinical setting.[115] long with the aforementioned potential targets, a number of KRAS-specific synthetic interactions have been rece…”
BackgroundAurora kinase targeting in lung cancer reduces KRAS-induced transformation
dos Santos, E. O., Carneiro-Lobo, T. C., Aoki, M. N., Levantini, E., & Bassères, D. S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0494-6 · Cited by 64
“Considering that targeting traditional KRAS effectors has so far had limited success [1, 4], the identification of novel KRAS targets that impinge on the oncogenic phenotype is warranted in order to increase the possibilities of combinatorial therapy design and achieve therapeutic efficacy.”
BackgroundAn engineered protein antagonist of K-Ras/B-Raf interaction
Kauke, M. J., Traxlmayr, M. W., Parker, J. A., Kiefer, J. D., Knihtila, R., McGee, J., Verdine, G., Mattos, C., & Wittrup, K. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-05889-7 · Cited by 64
Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019
Charo, L. M., & Plaxe, S. C. (2019) · F1000Research · doi:10.12688/f1000research.17408.1 · Cited by 63
Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System
Röth, S., Macartney, T. J., Konopacka, A., Chan, K.-H., Zhou, H., Queisser, M. A., & Sapkota, G. P. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.06.012 · Cited by 63
Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1
Tajiri, H., Uruno, T., Shirai, T., Takaya, D., Matsunaga, S., Setoyama, D., Watanabe, M., Kukimoto-Niino, M., Oisaki, K., Ushijima, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.016 · Cited by 57
“Accumulating evidence indicates that mutations activating RAS family members, K-RAS, H-RAS, and N-RAS, are found in 20%–30% of human tumors (Cox et al., 2014; Prior et al., 2012; Spiegel et al., 2014), thereby placing thesemutations as major drivers of cancers.”
BackgroundSmall Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Xu, K., Park, D., Magis, A. T., Zhang, J., Zhou, W., Sica, G., Ramalingam, S. S., Curran, W. J., & Deng, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1012-4 · Cited by 75
Shin, S.-M., Kim, J.-S., Park, S.-W., Jun, S.-Y., Kweon, H.-J., Choi, D.-K., Lee, D., Cho, Y. B., & Kim, Y.-S. (2020) · Science Advances · doi:10.1126/sciadv.aay2174 · Cited by 63
Simultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles
Yu, Z., He, X., Wang, R., Xu, X., Zhang, Z., Ding, K., Zhang, Z., Tan, Y., & Li, Z. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c05899 · Cited by 63
A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer
Zhao, X., Wang, X., Fang, L., Lan, C., Zheng, X., Wang, Y., Zhang, Y., Han, X., Liu, S., Cheng, K., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.015 · Cited by 67
Recent Advances and Perspectives in Cancer Drug Design
Magalhães, L. G., Ferreira, L. L. G., & Andricopulo, A. D. (2018) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201820170823 · Cited by 80
Cao, S., Chung, S., Kim, S., Li, Z., Manor, D., & Buck, M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004021 · Cited by 67
“G12V with PIP2 doped DOPC lipid vesicles without (red) and with (green) Gd3+ spin-labeled lipid.”
BackgroundMethodInfluentialRAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer
Maffeis, V., Nicolè, L., & Cappellesso, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01255 · Cited by 74
“Indeed, KRAS mutations are usually detected in colorectal, pancreatic, biliary tract, and lung carcinomas,NRASmutation inmalignantmelanomas, andHRAS mutation in head and neck carcinomas (41, 42).”
BackgroundThyroid C-Cell Biology and Oncogenic Transformation
Cote, G. J., Grubbs, E. G., & Hofmann, M.-C. C. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-22542-5_1 · Cited by 70
Tripathi, K., & Garg, M. (2018) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0441-3 · Cited by 66
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
“Second, the efforts of trying to design small molecules blocking the GTP binding site on K-Ras have been challenging, given the extremely high affinity of K-Ras for GTP.(41,45) These failures have led to the perception that K-Ras is not druggable.”
Park, J.-O., Pandya, V., Ezekiel, S. J., & Berghuis, A. M. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2020.612728 · Cited by 64
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
Gu, M., Xu, T., & Chang, P. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006950 · Cited by 70
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Désage, A.-L., Léonce, C., Swalduz, A., & Ortiz-Cuaran, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.796832 · Cited by 60
“picomolar affinity of RAS for GTP and the smooth surface of KRAS with a lack of well-defined hydrophobic pocket prevented either the development of GTP inhibitors or the development of KRAS inhibitors (66).”
BackgroundProtease-controlled secretion and display of intercellular signals
Vlahos, A. E., Kang, J., Aldrete, C. A., Zhu, R., Chong, L. S., Elowitz, M. B., & Gao, X. J. (2022) · Nature Communications · doi:10.1038/s41467-022-28623-y · Cited by 67
Recent progress on MAP kinase pathway inhibitors
Uehling, D., & Harris, P. A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.093 · Cited by 68
Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies
Waters, A. M., Ozkan-Dagliyan, I., Vaseva, A. V., Fer, N., Strathern, L. A., Hobbs, G. A., Tessier-Cloutier, B., Gillette, W. K., Bagni, R., Whiteley, G. R., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aao3332 · Cited by 61
Self-citationPotentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator
Pan, J., Zhang, Q., Palen, K. A., Wang, L., Qiao, L., Johnson, B. D., Sei, S., Shoemaker, R. H., Lubet, R. A., Wang, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.044 · Cited by 65
Structure of two G-quadruplexes in equilibrium in the KRAS promoter
Marquevielle, J., Robert, C., Lagrabette, O., Wahid, M., Bourdoncle, A., Xodo, L. E., Mergny, J., & Salgado, G. F. J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa387 · Cited by 67
“As the anti-KRAS strategies currently tested did not give satisfactory results for clinical applications (8), new therapeutic approaches focus on upstream elements, by targeting mRNA or directly the gene and its promoter regions (19).”
BackgroundTirella, A., Kloc-Muniak, K., Good, L., Ridden, J., Ashford, M., Puri, S., & Tirelli, N. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.02.032 · Cited by 60
Ray, P., Dutta, D., Haque, I., Nair, G., Mohammed, J., Parmer, M., Kale, N. R., Orr, M., Jain, P., Banerjee, S., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00499 · Cited by 62
Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets
Tate, E. W., Soday, L., de la Lastra, A. L., Wang, M., & Lin, H. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00666-x · Cited by 69
“Similarly, ABHD17 appears to be the dominant NRAS deacylase, but loss of function through knockout or treatment with the specific small-molecule inhibitor ABD957 had modest impacts on NRAS deacylation and cancer cell growth in NRAS-mutant AML cell lines, although these were enhanced in combination with a MEK inhibitor…”
InfluentialHarms, P. W., Hovelson, D. H., Cani, A. K., Omata, K., Haller, M. J., Wang, M. L., Arps, D. P., Patel, R. M., Fullen, D. R., Wang, M., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.12.015 · Cited by 63
“Both mutations have been previously described as activating [20].”
BackgroundResistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
Blaquier, J. B., Cardona, A. F., & Recondo, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.787585 · Cited by 57
“Moreover, the lack of allosteric regulatory sites needed for drug binding coined KRAS as an “undruggable” target (10).”
BackgroundNaidu, S., Shi, L., Magee, P., Middleton, J. D., Laganà, A., Sahoo, S., Leong, H. S., Galvin, M., Frese, K. K., Dive, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14843-6 · Cited by 60
Desmoplakin maintains gap junctions by inhibiting Ras/MAPK and lysosomal degradation of connexin-43
Kam, C. Y., Dubash, A. D., Magistrati, E., Polo, S., Satchell, K. J. F., Sheikh, F., Lampe, P. D., & Green, K. J. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201710161 · Cited by 59
“To date, there have been no pharmacological inhibitors of Ras that have made it to the clinic despite massive efforts to target this pathway given its prevalence in human cancers, prompting the assertion that Ras proteins are “undruggable” (Baines et al., 2011; Cox et al., 2014).”
BackgroundCancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis
Guo, S. (2018) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12221 · Cited by 60
Sheffels, E., Sealover, N. E., Wang, C., Kim, D. H., Vazirani, I. A., Lee, E., M. Terrell, E., Morrison, D. K., Luo, J., & Kortum, R. L. (2018) · Science Signaling · doi:10.1126/scisignal.aar8371 · Cited by 56
Self-citationCodon usage regulates human KRAS expression at both transcriptional and translational levels
Fu, J., Dang, Y., Counter, C. M., & Liu, Y. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004908 · Cited by 66
“With regards to the latter, these genes are collectively mutated in one-third of all human cancers (5).”
BackgroundPost-Translational Modification and Subcellular Distribution of Rac1: An Update
Abdrabou, A., & Wang, Z. (2018) · Cells · doi:10.3390/cells7120263 · Cited by 61
“Until recently, Rac1 itself was considered “undruggable” by small molecules due to the lack of any deep hydrophobic pockets on the surface and earlier failure in finding effective pharmacologic inhibitors [21] The main approach was to target its downstream effectors of kinases such as PAK [22].”
BackgroundYang, H., Liang, S.-Q., Xu, D., Yang, Z., Marti, T. M., Gao, Y., Kocher, G. J., Zhao, H., Schmid, R. A., & Peng, R.-W. (2019) · Oncogenesis · doi:10.1038/s41389-019-0158-7 · Cited by 58
FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance
Bartel, C. A., Parameswaran, N., Cipriano, R., & Jackson, M. W. (2016) · Oncotarget · doi:10.18632/oncotarget.9544 · Cited by 64
The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets
Abramson, H. N. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.015 · Cited by 62
KRAS: the Achilles’ heel of pancreas cancer biology
Drizyte‐Miller, K., Talabi, T., Somasundaram, A., Cox, A. D., & Der, C. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191939 · Cited by 73
“This modification was shown to be required for KRAS association with plasma membrane and for downstream signaling and cell transformation (49).”
Self-citationMolecular driver alterations and their clinical relevance in cancer of unknown primary site
Löffler, H., Pfarr, N., Kriegsmann, M., Endris, V., Hielscher, T., Lohneis, P., Folprecht, G., Stenzinger, A., Dietel, M., Weichert, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10035 · Cited by 64
“KRAS mutations indicating a poor prognosis and, at the same time, predicting lack of response to therapies targeting EGFR, since it is well established that their action requires an intact downstream RAS pathway [34, 36].”
K-RasG12D Has a Potential Allosteric Small Molecule Binding Site
Feng, H., Zhang, Y., Bos, P. H., Chambers, J. M., Dupont, M. M., & Stockwell, B. R. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01300 · Cited by 57
Gross, A. M., Frone, M. N., Gripp, K. W., Gelb, B. D., Schoyer, L., Schill, L., Stronach, B. E., Biesecker, L. G., Esposito, D., Hernandez, E. R., et al. (2020) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61485 · Cited by 57
“In sporadic cancer, RAS isoforms are somatically mutated at three main hotspots (Gly12, Gly13, and Gln61); these variants render RAS GAPinsensitive, and thus persistently GTP-bound and active (Cox et al., 2014; Cox & Der, 2002, 2010).”
BackgroundCancer vaccines: Targeting KRAS-driven cancers
Zhang, Y., Ma, J., Zhang, H.-X., Jiang, Y., & Luo, W. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1733420 · Cited by 63
“KRAS mutations also represent a poor prognosis for advanced NSCLC or PDAC cancers treated with chemotherapeutics [12,13] or EGFR tyrosine kinase inhibitors (TKIs) [14].”
BackgroundInfluentialSammarco, G., Gallo, G., Vescio, G., Picciariello, A., Paola, G. D., Trompetto, M., Currò, G., & Ammendola, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092852 · Cited by 61
Protein Prenyltransferases and Their Inhibitors: Structural and Functional Characterization
Marchwicka, A., Kamińska, D., Monirialamdari, M., Błażewska, K. M., & Gendaszewska‐Darmach, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105424 · Cited by 61
“Therefore, targeting of small GTPases through the inhibitors affecting membrane localization by the inhibition of prenyltransferases has entered the spotlight [12].”
BackgroundImmune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
Li, X., Gulati, M., Larson, A. C., Solheim, J. C., Jain, M., Kumar, S., & Batra, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.009 · Cited by 58
Total Chemical Synthesis and Folding of All- l and All- d Variants of Oncogenic KRas(G12V)
Levinson, A. M., McGee, J. H., Roberts, A. G., Creech, G. S., Wang, T., Peterson, M. T., Hendrickson, R. C., Verdine, G. L., & Danishefsky, S. J. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b02988 · Cited by 57
Bery, N., Cruz-Migoni, A., Bataille, C. J., Quevedo, C. E., Tulmin, H., Miller, A., Russell, A., Phillips, S. E., Carr, S. B., & Rabbitts, T. H. (2018) · eLife · doi:10.7554/elife.37122 · Cited by 55
“RAS has been regarded as undruggable partly because so far attempts to interfere with the protein have not been efficacious (Cox et al., 2014).”
BackgroundMethodMalignant Transformation and Associated Biomarkers of Ovarian Endometriosis: A Narrative Review
Михалева, Л. М., Davydov, A. I., Игоревна, П. О., Вячеславовна, М. Е., Nikolenko, V. N., Неганова, М. Е., Klochkov, S. G., Somasundaram, S. G., Kirkland, C. E., & Aliev, G. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01363-5 · Cited by 62
Drug design targeting active posttranslational modification protein isoforms
Meng, F., Liang, Z. T., Zhao, K., & Luo, C. (2020) · Medicinal Research Reviews · doi:10.1002/med.21774 · Cited by 61
Liang, S.-Q., Bührer, E. D., Berezowska, S., Marti, T. M., Xu, D., Froment, L., Yang, H., Hall, S. R. R., Vassella, E., Yang, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0479-6 · Cited by 55
Savva, L., & Georgiades, S. N. (2021) · Molecules · doi:10.3390/molecules26040841 · Cited by 59
“KRAS mutations are major oncogenic driver mutations in many cancers and considered of critical importance in acquisition of drug resistance by cancer cells [132,133].”
BackgroundSwidnicka-Siergiejko, A. K., Gomez-Chou, S. B., Cruz‐Monserrate, Z., Deng, D., Liu, Y., Huang, H., Ji, B., Azizian, N. G., Daniluk, J., Lu, W., et al. (2016) · Oncogene · doi:10.1038/onc.2016.461 · Cited by 55
USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer
Fraile, J. M., Manchado, E., Lujambio, A., Quesada, V., Campos-Iglesias, D., Webb, T. R., Lowe, S. W., López-Otín, C., & Freije, J. M. P. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.762757 · Cited by 69
“However, the therapeutic targeting of this oncogene has been challenging so far and there is a clear need of effective treatment for cancers harboring oncogenic mutations in KRAS (5, 6).”
BackgroundTargeting the α4–α5 dimerization interface of K-RAS inhibits tumor formation in vivo
Khan, I., Spencer-Smith, R., & O’Bryan, J. P. (2019) · Oncogene · doi:10.1038/s41388-018-0636-y · Cited by 54
Sayyed-Ahmad, A., Prakash, P., & Gorfe, A. A. (2017) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25317 · Cited by 54
PAF remodels the DREAM complex to bypass cell quiescence and promote lung tumorigenesis
Kim, M. J., Cervantes, C., Jung, Y., Zhang, X., Zhang, J., Lee, S. H., Jun, S., Litovchick, L., Wang, W., Chen, J., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.02.001 · Cited by 61
Application of Thiol–yne/Thiol–ene Reactions for Peptide and Protein Macrocyclizations
Wang, Y., Bruno, B. J., Cornillie, S. P., Nogieira, J. M., Chen, D., Cheatham, T. E., Lim, C. S., & Chou, D. H. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201700572 · Cited by 60
Leung, E. L., Luo, L. X., Liu, Z. Q., Wong, V. K. W., Lu, L., Xie, Y., Zhang, N., Qu, Y. Q., Fan, X., Li, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0065-9 · Cited by 60
Metadata
- Authors
- Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- Corresponding author
- Der, Channing J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-10-17
- Volume
- 13
- Issue
- 11
- Pages
- 828-851
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4355017
- OpenAlex
- W2081990599
- Cited by
- 1,997
- References
- 231
- Citations by year
- 2026: 134 · 2025: 160 · 2024: 194 · 2023: 185 · 2022: 213 · 2021: 237 · 2020: 204 · 2019: 166 · 2018: 156 · 2017: 166 · 2016: 106 · 2015: 71 · 2014: 2
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (DP1OD006933, 5r01ca042978-30)
- U.S. Public Health Service (P50A095103-12)
- National Cancer Institute (P50CA127003, CA042978, R01CA175747, DP1CA174419, P50CA095103, CA175747, R01-CA042978, R21CA179193, RC2CA148375, CA179193, R01CA157490)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS inhibitors, undruggable targets, synthetic lethality, RAS-mutant cancers, anticancer drug discovery, Ras signaling
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Signal Transduction, Oncogene Proteins, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.